Multiple studies have investigated the possible involvement—also in MASLD pathophysiology—of molecular mechanisms initially identified as exclusive of bone disease, with a focus on receptor activator of NF-κB (RANK), receptor activator of NF-κB ligand (RANKL), and osteoprotegerin (OPG). This evidence concerns the gene TNFRSF11A and metabolic dysfunction-associated steatotic liver disease.